AtoCap’s team combines world-class academic, clinical and commercialisation expertise and has a strong track record of successfully translating highly innovative technologies into commercial opportunities that generate substantive income and impact endpoints for stakeholders and investors.
The team initially developed from within University College London’s Encapsulation Research Group and is based on a novel implementation of electro-hydrodynamic processing for the preparation of a wide range of encapsulated structures via a clean, efficient, one-step route.
Microencapsulation: AtoCap Technology enables the encapsulation of patient-specific combinations of generic drugs such as antibiotics and chemotherapeutics into a multi-layered capsule.
Our first product, CapFuran®, enables time-release killing of a variety of patient-derived uropathogenic bacterial species, including E. coli, by a well-known and frequently-used generic antibiotic encapsulated using innovative methodology. In pre-clinical experiments, CapFuran® eradicated bacteria buried deep within a multi-layered human bladder organoid model and also killed bacterial biofilms.
Targeted and Penetrative Delivery: The capsules can be delivered by a single, minimally invasive outpatient procedure.
Flexible and Versatile: The multi-layered capsule formulation allows for both immediate and sustained release of the drug precisely where it is required. The capsules can be adapted to deliver multiple other drug cargos to treat a variety of clinical indications.
The principal area of clinical application on which the business is currently focused is targeted antibiotic delivery for recurrent and chronic urinary tract infections (UTI). UTI is one of the most common infectious diseases worldwide, affecting over 150 million patients per year globally and particularly the growing elderly population. The global market is estimated at US$10M per annum.
The current approach to systemic antibiotic treatment is fraught with limitations: